Effect on Morphology, Osmotic Fragility and Electro Kinetic Potential of Erythrocytes in Hypertension.

BACKGROUND: Hypertension is a common health problem concerning a large proportion of population and a leading global risk factor for the burden of cardiovascular disease (CVD). The purpose of this study was to assess the efficacy of the erythrocyte zeta potential as a potential additional indicator for cardiovascular disorder risk so that patients with this can be more rapidly identified and treated. METHODS: In the present study, blood samples were collected in 5% dextrose solution from patients suffering from hypertension and healthy volunteers (Not taken any medication). The mobility of individual RBCs was tracked by equipped Zeta meter-ZM4DAQ software using microscopicallyacquired video images, data were recorded 10 times for each sample and average zeta-potential in mv was recorded. RESULTS: We found that mean erythrocytic ZP of control group was found to be 23.41 mv (± 1.87) whereas, erythrocytic ZP for Hypertensive patients was found to be 16.05 (±1.72) mV and Hypertensive patients with Diabetes is much lower from 6.96 mV to 22.76 (+3.88) mV along with structural deformities and increased osmotic fragility of erythrocytes. CONCLUSION: The data suggest that there are morphological changes in erythrocyte structure, increased osmotic fragility along with significantly lower ZP value as compared to that of healthy volunteers which may be the major cause for progression to the development of cardiovascular disease.

Novel biomaterial for transdermal application: in vitro and in vivo characterization.

The objective of the present study was to evaluate a novel film forming biomaterial for its potential application in the preparation of unilaminate transdermal adhesive matrix systems. The biomaterial, Damar Batu (DB), was tried alone and in combination with Eudragit RL100 as a matrixing agent in the preparation of transdermal patches. Developed transdermal patches of Diltiazem hydrochloride (DH) were evaluated for thickness uniformity, weight uniformity, folding endurance and drug content. USP dissolution apparatus V was used for in vitro drug release studies. Modified Franz diffusion cell used for permeation study using excised human cadaver skin. Total 6 formulations were developed and on the basis of in vitro drug release and in vitro skin permeation profile F5 composed of DB: Eudragit RL100 (60:40) and carrying 20 %w/w DH was selected as an optimized formulation for in vivo study. The in vivo study results showed that F5 achieved the Cmax of about 269.76 ± 1.52 ng/mL in 6 h and sustained the release of the drug till 24 h. The skin irritation study results proved that the novel biomaterial is non-sensitizing and non-irritating. Drug-polymer interaction study carried out to check the compatibility of drug and polymer showed the intactness of the drug in the formulation proving the compatibility of the polymer. It can be proposed from the outcome of the present study that by applying suitable adhesive layer and backing membrane, DB: Eudragit RL100 (60:40) transdermal patches can be of potential therapeutic use.

Damar Batu as a novel matrix former for the transdermal drug delivery: in vitro evaluation.

PURPOSE: Damar Batu (DB) is a novel film-forming biomaterial obtained from Shorea species, evaluated in this study for its potential application in transdermal drug delivery system. METHODS: DB was characterized initially in terms of acid value, softening point, molecular weight (M(w)), polydispersity index (M(w)/M(n)), and glass transition temperature (T(g)). Neat, plasticized films of DB were investigated for mechanical properties. The biomaterial was further investigated as a matrix-forming agent for transdermal drug delivery system. Developed matrix-type transdermal patches were evaluated for thickness and weight uniformity, folding endurance, drug content, in vitro drug release study, and skin permeation study. RESULTS: On the basis of in vitro drug release and in vitro skin permeation performance, formulation containing DB/Eudragit RL100 (60 : 40) was found to be better than other formulations and was selected as the optimized formulation. IR analysis of physical mixture of drug and polymer and thin layer chromatography study exhibited compatibility between drug and polymer. CONCLUSION: From the outcome of this study, it can be concluded that applying suitable adhesive layer and backing membrane-developed DB/ERL100, transdermal patches can be of potential therapeutic use.

Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000.

The aim of the present study was to enhance the dissolution rate of gliclazide using its solid dispersions (SDs) with polyethylene glycol (PEG) 6000. The phase solubility behavior of gliclazide in presence of various concentrations of PEG 6000 in 0.1 N HCl was obtained at 37 degrees C. The solubility of gliclazide increased with increasing amount of PEG 6000 in water. Gibbs free energy (deltaG(o)(tr)) values were all negative, indicating the spontaneous nature of gliclazide solubilization and they decreased with increase in the PEG 6000 concentration, demonstrating that the reaction conditions became more favorable as the concentration of PEG 6000 increased. The SDs of gliclazide with PEG 6000 were prepared at 1:1, 1:2 and 1:5 (gliclazide/PEG 6000) ratio by melting-solvent method and solvent evaporation method. Evaluation of the properties of the SDs was performed by using dissolution, Fourier-transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies. The SDs of gliclazide with PEG 6000 exhibited enhanced dissolution rate of gliclazide, and the rate increased with increasing concentration of PEG 6000 in SDs. Mean dissolution time (MDT)of gliclazide decreased significantly after preparation of SDs and physical mixture with PEG 6000. The FTIR spectroscopic studies showed the stability of gliclazide and absence of well-defined gliclazide-PEG 6000 interaction. The DSC and XRD studies indicated the microcrystalline or amorphous state of gliclazide in SDs of gliclazide with PEG 6000.